Rigel Pharmaceuticals, Inc. (RIGL)

Rigel Pharmaceuticals' stock experienced a significant increase in August 2025 due to a substantial earnings beat and raised guidance. Following Q3 2025 results, the company announced record net product sales and increased its full-year 2025 revenue guidance. Analyst ratings impacted the stock, with Cantor Fitzgerald increasing its target price and Wall Street Zen upgrading shares. In January 2026, Rigel provided a business update and its 2026 outlook, anticipating positive net income. Citigroup reiterated a "buy" rating, but Zacks Research downgraded Rigel. As of February 7, 2026, the consensus recommendation was "Hold," with an average 12-month price target of $43.20.

There is no explicit information indicating significant demand seasonality for Rigel Pharmaceuticals' products and services. Demand is generally driven by ongoing patient needs rather than seasonal fluctuations.

Rigel Pharmaceuticals is a biotechnology company focused on discovering, developing, and providing therapies for hematologic disorders and cancer. The company develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. Its commercialized products include Tavalisse for chronic immune thrombocytopenia, Rezlidhia for relapsed or refractory acute myeloid leukemia, and Gavreto for non-small cell lung cancer and thyroid cancer. Rigel also has a pipeline product, R289, being developed for hematology-oncology, autoimmune, and inflammatory diseases.

Rigel Pharmaceuticals is headquartered in South San Francisco, California. The company's international presence is expanding through partnerships, facilitating the launch of Tavalisse in markets such as South Korea and Mexico.

Rigel Pharmaceuticals' brand reputation has been influenced by positive commercial performance and some analyst downgrades. Strong commercial execution and clinical advancement of its R289 pipeline asset positively impact its standing. However, a lower news sentiment score and a downgrade from Zacks Research indicate a mixed public perception. An increase in short interest and a negative Altman Z-Score also affect its reputation.

Rigel Pharmaceuticals has a significant concentration of ownership among institutional investors, who collectively hold the largest stake, accounting for 76.87% of the company as of late 2025. As of February 2, 2026, there were 301 institutional owners holding a total of 16,858,523 shares. Major institutional shareholders include BlackRock, Inc., Vanguard Group Inc, Goldman Sachs Group Inc, Armistice Capital, Llc, Acadian Asset Management Llc, Marshall Wace, Llp, Capitolis Liquid Global Markets LLC, State Street Corp, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, and Renaissance Technologies Llc. Vanguard Group Inc was the top institutional holder as of December 2025, with 1.04 million shares, representing 5.43% of the company. Insiders hold 7.35% of the stock as of late 2025.